BrainStorm Cell Therapeutics announced it has begun training the cell manufacturing team at City of Hope's Center for Biomedicine and Genetics to produce clinical supplies of NurOwn adult stem cells for the company's randomized, double-blind, multi-dose Phase 3 clinical study in patients with Amyotrophic Lateral Sclerosis (ALS). City of Hope will be the clinical supplier for all U.S. medical centers participating in the Phase 3 trial.
"City of Hope is one of the world's pre-eminent cell product manufacturing centers," Chaim Lebovits, President and CEO of BrainStorm said. "The transfer of our proprietary autologous cell production technology to City of Hope's production team reflects the rapid progress we are making in preparing for our Phase 3 ALS clinical study and will ensure that we have adequate high-quality cell-production capacity in place when we begin the Phase 3 study. We welcome them as a clinical partner and appreciate their commitment to the success of this important clinical program."
"BrainStorm's NurOwn technology represents an innovative approach to treating ALS. City of Hope is excited to play a role in treating this devastating disease," Joseph Gold, PhD, Director of manufacturing at the Center for Biomedicine and Genetics said.